Fig 1: CD56bright NK cells expanded in IL-2 and TGF-β1 exhibit regulatory functions in vitro(A) Method of NK cell isolation, PBMCs were stained with FITC conjugated antibodies for the following lineage markers: CD3, CD4, CD8α, CD14, CD15, CD19, CD20, TCRαβ, TCRδγ, CD33, CD34, CD203c, FCεr1α, CD79α, and CD138. NK were sorted as live CD56brightCD16− or CD56dimCD16+, and CCR6− and CRTH2− to exclude ILC2s and ILC3s.(B) Representative gating strategy to sort CD56brightCD16− NK cells and CD56dimCD16+ NK cells from healthy PBMCs.(C) Fold expansion of NK cells after 19 days of in vitro culture in IL-2, IL-15, and IL-18 cytokines, or IL-2, TGF-β1, and anti-IFN-γ referred to as NKconv and NKTGF-β, respectively.(D) Representative and summary cytokine expression of CD56bright NKconv and NKTGF- β at day 20 post-expansion, stimulated with phorbol 12-mystrate 13-acetate (PMA)/ionomycin for a duration of 6 h (n = 7, 3).(E) Active TGF-β1 within supernatants of NK cells plated at 1 M/mL at D20 (n = 14, 16).(F and G) Naive autologous CD4+ T cells were labeled with cell proliferation dye (CPD) for a short term 4-day culture with either NKconv (n = 4) or NKTGF-β (n = 6) with anti-CD3 and anti-CD28 antibodies. Suppression was measured by percent divided of the live CD3+ CD4+ CD56− CD8− in comparison to naive CD4+ T cells activated with anti-CD3 and anti-CD28 antibodies. Dashed line indicates 0 percent suppression.(H) Summary of CPD+ HELIX-NP+ and Annexin-V+ K562 cells. Helix-NP+Annexin-V+ indicates apoptotic cells (n = 5, 6).(I) Expression of FOXP3 and CD25 within co-cultures with NK cells (n = 3–6).(J) Following 20 days co-culture of CD4+ T cells with IL-2 and TGF-β1-treated CD56bright NK cells, CD25+CD127low/− T cells were sorted then co-cultured with CPD stained allogeneic naive T cells for 3 days (n = 3, 4). Induced Tregs (iTregs) were generated using standard induction protocols of IL-2 and TGF-β1 (n = 3, 4). Suppression as measured by percent divided of CD4+CD3+CPD+ T cells.Asterisk indicates a significant difference, ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. Significance was determined by Kruskal-Wallis test (C–E and G), (F) Mann-Whitney U test, and (I) Signed Wilcoxon-rank test. Data are represented as mean ± SEM (D and I) or median (E, F, H, and I) are shown.
Fig 2: Calhm6 −/− macrophages and NK cells are capable of normal responses to activating signals when stimulated in isolation, in vitro A, B WT and Calhm6 −/− mice were injected i.p. with Poly(I:C) (200 μg/mouse) or PBS. On day 3 spleens were collected, stained with antibodies against NK cell‐maturation markers and analysed by flow cytometry. Representative contour plots (A) and pooled flow cytometry results (B) are shown (results from one experiment, Poly(I:C) WT mice = 5, Calhm6 −/− mice = 5, control WT mice = 2, Calhm6 −/− mice = 2 mice, One‐way ANOVA with multiple comparisons).C CD3−NK1.1+ cells were isolated from naïve mouse spleens and stimulated in vitro with PMA/ionomycin, IL‐12 (50 ng/ml), TNF (50 ng/ml), or IL‐18 (50 ng/ml). After 6 h stimulation, supernatant was collected and IFN‐γ was measured by ELISA (pooled results from two independent experiments, Untreated and PMA stimulation WT mice = 6, Calhm6 −/− mice = 6, TNF + IL‐12 stimulation: WT mice = 3, Calhm6 −/− mice = 3, otherwise WT mice = 3, Calhm6 −/− mice = 2, One‐way ANOVA with multiple comparisons).D, E BMDM with or without 24 h IFN‐γ priming were grown in antibiotic‐free medium, washed and cultured with Listeria monocytogenes (MOI 1) for 30 min, at which time gentamicin (5 ng/ml) was added to the medium to kill extracellular bacteria. Supernatant from BMDM infected with L. monocytogenes was collected after 6 h. IL‐1β (D, pooled results from five independent experiments, WT mice = 5, Calhm6 −/− mice = 5, Kruskal–Wallis test) and IL‐18 concentration (E, pooled results from three independent experiments, WT mice = 3, Calhm6 −/− mice = 3, Kruskal–Wallis test) were quantified by ELISA, and normalised to WT set to 100%, to allow pooling of independent experiments.F NO production in WT and Calhm6 −/− BMDM treated overnight with LPS or Poly(I:C) quantified with a Griess test on cell supernatant (results from one experiment, WT mice = 3, Calhm6 −/− mice = 3, Kruskal–Wallis test with multiple comparisons).G BMDM with or without IFN‐γ priming were grown overnight in antibiotic‐free medium. Cells were infected with L. monocytogenes (MOI 1) for 30 min. Gentamicin (5 ng/ml) was then added to the medium to kill extracellular bacteria. At 0, 4 and 8 h cells were harvested, lysed with 0.1% Triton X‐100 and the lysate was plated on antibiotic‐free BHI plates for 24 h, and CFU were quantified (pooled results from three independent experiments, WT mice = 3, Calhm6 −/− mice = 3, Two‐way ANOVA test). Data information: Error bars represent SD. Source data are available online for this figure.
Fig 3: IL-18 promotes the production of terminal effector Treg cells with stronger immunosuppressive function via the ERK/NF-κB pathway. (A) Schematic diagram indicating the 100 µm range around the mapping spots of Treg cells in cluster 5. (B) Quantification of activated CD4+ and CD8+ T cells within 100 µm around six groups of Treg cells from patients. *p<0.05, **p<0.01, ****p<0.0001; one-way ANOVA. (C) UMAP with superimposed RNA velocity analysis of the Treg cell subsets. (D) Heatmap and violin plot showing differentially expressed cytokine/chemokine receptor genes across Treg cell subclusters. (E) Flowchart for inducing IL-1β+ Treg cell in vitro experiments. (F) Reverse transcription-quantitative PCR analysis of IL1B expression in Treg cells from peripheral blood mononuclear cells of patients with clear cell renal cell carcinoma. ***p<0.001, ****p<0.0001; one-way ANOVA test. (G) Quantification of IL-1β+ Treg cells (percentage of IL-1β+ cells pre-gated on CD4+FoxP3+ Treg cells) with/without simulation with IL-18. *p<0.05, one-way ANOVA test. (H)(I) Proliferation of CD8+ Tresp cells co-cultured with Treg cells or IL-1β+ Treg cells in 1:0.25-1:1 ratio, assessed as CFSE dilution. (H) (J) Comparison of proliferation percentage of CD8+ Tresp cells co-cultured with Treg cells or IL-1β+ Treg cells in 1:0.25–1:1 ratio. ****p<0.0001; one-way ANOVA test. (K) The proportion of Ki-67-positive CD8+ Tresp cells co-cultured with Treg cells or IL-1β+ Treg cells in 1:0.25–1:1 ratio. ****p<0.0001; one-way ANOVA test. (L) IFN-γ production of CD8+ Tresp cells co-cultured with Treg cells or IL-1β+ Treg cells in 1:0.25–1:1 ratio. **p<0.01, ****p<0.0001; one-way ANOVA test. (M) Quantification of IL-1β+ Treg cells (percentage of IL-1β+ cells pre-gated on CD4+FoxP3+ Treg cells) with simulation of IL-18 and PMA/TBHQ (control is only stimulated with IL-18). **p<0.01, ***p<0.001; one-way ANOVA test. (N) (O) Western blot analysis results of the Treg cells treated with 50 ng/mL IL-18 with or without 5 µM U0126 or BAY 11–7082 were determined. U0126: an ERK inhibitor, BAY 11–7082: an NF-κB inhibitor (O) Quantification of the expression levels of the proteins in (N). *p<0.05, ***p<0.001, ****p<0.0001; one-way ANOVA test. ANOVA, analysis of variance; CFSE, carboxyfluorescein diacetate succinimidyl ester; IFN, interferon; IL, interleukin; NC, negative control, unstimulated CD8+ Tresp cells only; PC, positive control, stimulated CD8+ Tresp cells only; PMA, phorbol 12-myristate 13-acetate, an NF-κB activator; TBHQ, tert-butylhydroquinone, an ERK activator; Treg, regulatory T cell; Tresp, proliferation of responder T; UMAP, uniform manifold approximation and projection.
Fig 4: MAP4K1 enhances the expression of IL-18R and IL-6R and promotes the proliferation of glioblastoma multiforme cells.(A) Real-time quantitative PCR analyses of IL-18R and IL-6R mRNA levels in MAP4K1-knockdown (KD) U87 and T98G cells and their negative control (NC) cells (n = 9, the data were from three independent experiments). (B) IL-18R and IL-6R protein expression detected by immunohistochemistry in mouse glioma tissues constructed by MAP4K1-KD (n = 3) and NC (n = 8) of U87 cells. Scale bar, 50 μm. (C, D, E) Respective flow cytometry histograms and relative levels of the mean fluorescence intensity for membrane-bound IL-18R in MAP4K1-KD or knockout (MAP4K1−/−) U87, T98G, and respective control cells 48 h after seeding (n = 3, the data were from an independent experiment, and the same experiment was repeated three times). (F, G, H) CCK8 assay of cell viability. The data were from three independent experiments. (F) MAP4K1-KD and NC cells were stimulated with IL-18 (100 ng/ml) and detected at different time points (24, 48, and 72 h) (n = 11). (G) MAP4K1−/− and MAP4K1+/+ T98G cells were treated with different doses of IL-18 (0, 50, and 100 ng/ml). (H) IL-18R was blocked with a neutralizing antibody (0, 1, 5 μg/ml). (G, H) Cell viability was determined at 96 h (n = 15 in (G, H)). In (A, C, D, E, F, G, H), data are presented as the mean ± SD. In (A, C, D, E), the data were analyzed by t tests. In (F, G, H), data were analyzed by two-way ANOVA. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig 5: Baricitinib inhibits cytokine-mediated increased infectivity of SARS-CoV-2 in organotypic primary human liver culture.(A) Immunofluorescence confocal imaging of a liver spheroid 48 hours after infection with SARS-CoV-2. Viral spike protein is shown in red, ACE2 in green, and DAPI (4′,6-diamidino-2-phenylindole) in blue. Arrows indicate examples of where spike protein and ACE2 signals are in close proximity. (B) Liver spheroids were treated with different cytokines (10 ng/ml), and the fold increase in ACE2 transcript levels are shown relative to controls (indicated by the solid line). Note that IFN-α2 and IFN-β significantly induce ACE2 levels. N = 2 technical replicates. (C) Combinatorial cytokine exposure does not result in increased ACE2 induction compared to IFN-α2 alone. “Other cytokines” corresponds to IFN-β, IFN-γ, TNFα, IL-1β, IL-6, IL-10, and IL-18. (D) IFN-α2 increases viral load in hepatocyte spheroids, and this effect is fully inhibited by baricitinib. N = 2 to 3 biological replicates. (E) IFN-α2–mediated induction of ACE2 is fully prevented by baricitinib. N = 3 biological replicates. All cytokine concentrations were 10 ng/ml unless stated otherwise. (F) ACE2 in lung organoids is not induced even by very high concentrations of IFN-α2 (50 ng/ml). N = 3 biological replicates. (G) By contrast, IFN-α2 slightly reduces viral load in lung organoids. N = 3 biological replicates. Error bars indicate SEM. A.U., arbitrary units; DMSO, dimethyl sulfoxide.
Supplier Page from BioLegend for Recombinant Human IL-18 (carrier-free)